Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Study Identifier:
C08-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
- Drug: Placebo
Date
Oct 2008 - Mar 2011
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years
Requirements Information
Sex
Female & Male
Age
18 - 80 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: eculizumab
- Drug: Placebo
Date
Oct 2008 - Mar 2011
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years years
Requirements Information
Protocol Summary
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.
Trial Locations
Location
Status
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Status
N/A
Location
University of California, Irvine
Orange, California, United States, 92868
Status
N/A
Location
University of California - Davis
Sacramento, California, United States, 95817
Status
N/A
Location
University of Florida & Shands Neuroscience Institute
Jacksonville, Florida, United States, 32209
Status
N/A
Location
Emory University
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Wishard Hospital
Indianapolis, Indiana, United States, 46202
Status
N/A